<DOC>
	<DOCNO>NCT00730353</DOCNO>
	<brief_summary>Paclitaxel know active single combination agent esophageal cancer , also demonstrate anti-angiogenic property weekly dose regimen . Sunitinib malate anti-angiogenic drug potential improve response combine chemotherapy , demonstrate regimen similar setting . We believe combination paclitaxel sunitinib malate offer great promise treatment advance esophageal cancer .</brief_summary>
	<brief_title>Sutent + Taxol Advanced Esophageal Cancer</brief_title>
	<detailed_description>OUTLINE : This multi-center study . Treatment administer outpatient basis . Chemotherapy administer 28-day treatment cycle . The 28 day treatment paclitaxel sunitinib malate ( plus time require recover toxicity encounter ) define cycle . - Paclitaxel 90 mg/m2 IV day 1 , 8 15 . - Sunitinib malate 37.5 mg orally , daily . After 4 cycle , paclitaxel discontinue patient continue sunitinib malate disease progression , unacceptable toxicity , physician discretion . Performance Status : ECOG ( Eastern Cooperative Oncology Group ) performance status 0 2 Life expectancy : Not specify Hematopoietic : - International Normalized Ratio ( INR ) &lt; 1.2 - Partial Thromboplastin Time ( PTT ) &lt; 1.5 x Upper Limit Normal ( ULN ) - Platelets &gt; 100 K/mm3 - Hemoglobin &gt; 8 g/dL - Absolute Neutrophil Count ( ANC ) &gt; 1.0 K/mm3 Hepatic : - Aspartate transaminase ( AST ) ≤ 2.5 x ULN , ≤ 5.0 x ULN transaminase elevation due know liver metastasis . - Alanine transaminase ( ALT ) ≤ 2.5 x ULN , ≤ 5.0 x ULN transaminase elevation due know liver metastasis . - Total bilirubin &lt; 2.0 x ULN Renal : - Serum creatinine ≤ 2 x ULN calculate creatinine clearance ( use Cockcroft-Gault formula ) &gt; 50 cc/min Cardiovascular : - No history unstable angina , myocardial infarction , coronary artery bypass graft surgery within 12 month prior registration protocol therapy . Patients may anti-anginal medication , must stable medication least 6 month . - No history New York Heart Association class II great congestive heart failure . Pulmonary : - Not specify</detailed_description>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologically confirm recurrent metastatic esophageal gastroesophageal junction squamous cell adenocarcinoma Measurable evaluable disease per RECIST within 28 day prior register protocol therapy . No one prior chemotherapy regimen locally advance metastatic disease allow . Written inform consent HIPAA authorization release personal health information . NOTE : HIPAA authorization may include informed consent obtain separately . Age &gt; 18 year . Females childbearing potential male must willing use effective method contraception ( hormonal barrier method birth control ; abstinence ) treatment 3 month period thereafter . Females childbearing potential must negative pregnancy test within 7 day prior register protocol therapy . Subjects consider child bear potential surgically sterile ( undergone hysterectomy , bilateral tubal ligation , bilateral oophorectomy ) postmenopausal . Females must breastfeed . Must willing comply study follow procedure . No history inadequately control hypertension ( Systolic Blood Pressure &gt; 150 Diastolic Blood Pressure &gt; 100 ) standard regimen antihypertensive therapy . No prior treatment vascular endothelial growth factor ( VEGF ) inhibitor , epidermal growth factor receptor ( EGFR ) inhibitor , antiangiogenic agent . No serious , nonhealing wound , ulcer , bone fracture . No history current hemoptysis . No history transient ischemic attack ( TIA ) stroke within 12 month prior registration protocol therapy . No evidence bleed diathesis , coagulopathy , prolong INR PTT . No chronic anticoagulation treatment . No history central nervous system brain metastasis . No history major surgical procedure , open biopsy , significant traumatic injury within 28 day prior registration protocol therapy , anticipation need major surgical procedure course protocol therapy . No history minor surgical procedure fine needle aspiration core biopsy within 7 day prior registration protocol therapy . No history clinically significant peripheral neuropathy , i.e. , Grade &gt; 3 neuromotor neurosensory toxicity define NCI CTCAE v 3.0 . No known history adrenal insufficiency document adrenocorticotropic hormone ( ACTH ) stimulation test . No prolonged correct QT ( QTc ) interval preentry electrocardiogram ( &gt; 450 msec ) , obtain within 28 day prior register protocol therapy . No active cancer No clinically significant infection judge treat investigator . No history seizure disorder . No known history hypersensitivity paclitaxel . No CYP3A4 inducer inhibitor allow within 14 day prior registration protocol therapy receive protocol therapy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>